BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoon YI, Lee SG. Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective. Dig Dis Sci 2019;64:993-1000. [PMID: 30895483 DOI: 10.1007/s10620-019-05551-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Limkemann AJ, Abreu P, Sapisochin G. How far can we go with hepatocellular carcinoma in living donor liver transplantation?: . Current Opinion in Organ Transplantation 2019;24:644-50. [DOI: 10.1097/mot.0000000000000692] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
2 Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W, Yang X, Wang B. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med 2021;10:7977-87. [PMID: 34605616 DOI: 10.1002/cam4.4312] [Reference Citation Analysis]
3 Kim S, Moon D, Park G, Lee S, Hwang S, Ahn C, Kim K, Ha T, Song G, Jung D, Yoon Y, Kim H. Preoperative prediction score of hepatocellular carcinoma recurrence in living donor liver transplantation: Validation of SNAPP score developed at Asan Medical Center. Am J Transplant 2021;21:604-13. [DOI: 10.1111/ajt.16227] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hwang S, Song GW, Ahn CS, Kim KH, Moon DB, Ha TY, Jung DH, Park GC, Yoon YI, Lee SG. Salvage living donor liver transplantation for hepatocellular carcinoma recurrence after hepatectomy: Quantitative prediction using ADV score. J Hepatobiliary Pancreat Sci 2021;28:1000-13. [PMID: 33175453 DOI: 10.1002/jhbp.863] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Lee S, Song GW, Kim KW, Kwon JH, Lee SG. Living Donor Liver Transplantation Versus Deceased Donor Liver Transplantation for Hepatocellular Carcinoma Within or Beyond the Milan Criteria: Comparable Long-Term Outcomes. Transplant Proc 2021;53:92-7. [PMID: 33288309 DOI: 10.1016/j.transproceed.2020.10.012] [Reference Citation Analysis]
6 Lu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z, Tang W. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer. 2019;18:130. [PMID: 31464625 DOI: 10.1186/s12943-019-1047-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 75] [Article Influence: 20.0] [Reference Citation Analysis]
7 Kim JM, Kim DG, Kim J, Lee K, Lee KW, Ryu JH, Kim BW, Choi DL, You YK, Kim DS, Nah YW, Kang KJ, Cho JY, Hong G, Yu HC, Moon JI, Choi D, Hwang S, Kim MS. Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry. Clin Mol Hepatol 2021;27:451-62. [PMID: 33525077 DOI: 10.3350/cmh.2020.0292] [Reference Citation Analysis]
8 Ren A, Li Z, Zhang X, Deng R, Ma Y. Inflammation-Based Prognostic Scores in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Transplantation. J Hepatocell Carcinoma 2020;7:101-6. [PMID: 32766175 DOI: 10.2147/JHC.S259992] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yoon YI, Song GW, Lee S, Moon D, Hwang S, Kang WH, Cho HD, Ha SM, Kim MJ, Kim SH, Na BG, Yang G, Min Kim S, Hyun Shim J, Park JI. Salvage living donor liver transplantation versus repeat liver resection for patients with recurrent hepatocellular carcinoma and Child-Pugh class A liver cirrhosis: A propensity score-matched comparison. Am J Transplant 2021. [PMID: 34383368 DOI: 10.1111/ajt.16790] [Reference Citation Analysis]